Latest news with #CLDN18.2
Al Etihad
a day ago
- Health
- Al Etihad
SEHA to host 3rd Best of ASCO UAE Conference
20 June 2025 20:25 ABU DHABI (ALETIHAD)SEHA part of PureHealth Group, in collaboration with Tawam Hospital, is proud to host the third edition of the Best of ASCO UAE Conference. The event will take place from June 21 - 22, 2025 at the Dusit Thani Hotel, Abu under license from the American Society of Clinical Oncology (ASCO), this prestigious regional conference brings to the UAE the most significant findings and presentations from the ASCO Annual Meeting held in Chicago from May 30 to June 3, 2025. With a strong emphasis on translating science into clinical practice, Best of ASCO UAE 2025 will serve as a key forum for international, regional, and local oncology experts to explore the latest research, evidence-based practices, and innovations in cancer conference will commence with pre-conference workshops on 20 June, including an Oncology Fellowship Masterclass and a dedicated Ovarian Cancer Workshop. The main event will feature eight core sessions addressing a broad spectrum of topics such as metastatic and early breast cancer, gastrointestinal malignancies, lung cancer, genitourinary cancers, head and neck cancers, and rare gynaecological cancers. These sessions will be complemented by parallel workshops exploring advanced treatment strategies, including the application of antibody-drug conjugates, targeted therapies such as CLDN 18.2 and PI3K inhibitors, and evolving approaches in the management of resectable and metastatic of ASCO UAE 2025 will welcome over 70 esteemed speakers from around the world, including internationally recognised experts such as Dr Debu Tripathy, Dr Gregory Vidal, Dr Martin Dietrich, and Dr Julie Gralow. They will be joined by a distinguished roster of regional and local oncology leaders from across the GCC and the UAE, ensuring a rich exchange of insights tailored to the region's clinical interactive Q&A sessions, case-based discussions, and networking opportunities, the conference promises to be a dynamic platform for translating the latest ASCO research into real-world clinical Hamda Salem Al Neyadi, Organising Committee Member of Best of ASCO UAE & Corporate Marketing & Communications Director at SEHA, said: 'Best of ASCO UAE 2025 is a strategic platform that underscores SEHA's role in shaping the future of oncology care in the region. By convening global thought leaders and translating cutting-edge research into actionable insights, we are not only elevating clinical practice but also reinforcing the UAE's position as a centre of excellence in healthcare innovation. This initiative reflects our broader vision to drive sustainable impact through knowledge exchange, strategic partnerships, and a relentless focus on improving patient outcomes.'Dr. Khalid Saeed Balaraj, Chair of the Oncology Centre at Tawam Hospital, commented: 'Hosting Best of ASCO for the third consecutive year reinforces our dedication to advancing cancer care through continuous learning. Tawam Hospital remains at the forefront of oncology services in the UAE, and we are proud to bring the global oncology community together to exchange knowledge and experiences.'Dr. Jawaher Ali Ansari, Chief of Medical Oncology at Tawam Hospital, said: 'The conference offers unparalleled access to the most current and clinically relevant data in oncology. Our goal is to empower healthcare professionals to apply the latest insights in practice, ultimately improving patient outcomes across the region.'As the UAE's national oncology centre, Tawam Hospital continues to uphold international standards of care while advancing Abu Dhabi's vision of becoming a hub for medical excellence and innovation. This initiative aligns with the strategic priorities of PureHealth, the UAE's largest integrated healthcare platform, which is committed to improving longevity and delivering future-ready healthcare across the Emirates.
Medscape
31-05-2025
- Business
- Medscape
CAR T-Cell Therapy Boosts PFS in Advanced Gastric Cancer
In patients with advanced Claudin-18 isoform 2 (CLDN18.2) -positive gastric or gastroesophageal junction cancers, satricabtagene autoleucel (satri-cel) chimeric antigen receptor (CAR) T-cell therapy significantly extended progression-free survival (PFS) compared with treatment of physician's choice (TPC). METHODOLOGY CLDN18.2, a tight-junction protein, is overexpressed in patients with gastric and gastroesophageal junction (GEJ) cancers. Satri-cel, an autologous CLDN18.2-specific CAR T-cell therapy, showed promise in previously treated patients with advanced disease, but further validation is needed. The new phase 2 randomized controlled trial involved 156 patients with pathologically confirmed CLDN18.2-positive advanced gastric or GEJ cancer who were refractory to two or more previous lines of treatment. The study was conducted in multiple centers in China, and the median age of participants was 52 years. Participants were randomly assigned in a 2:1 ratio to receive either satri-cel (IV infusion, up to three times at 250 × 10 6 cells; n = 104) or TPC (n = 52) that included nivolumab, paclitaxel, docetaxel, irinotecan, or rivoceranib. cells; n = 104) or TPC (n = 52) that included nivolumab, paclitaxel, docetaxel, irinotecan, or rivoceranib. In the satri-cel group, 85% of patients received at least one infusion of satri-cel, 31% received a second infusion, and 6% received a third infusion. In the TPC group, 92% of patients received at least one dose of their treatment. The primary endpoint was PFS assessed by a blinded independent review committee. The key secondary endpoint was overall survival (OS). The median follow-up time for PFS was 9.07 months in the satri-cel group and 3.45 months in the TPC group. The median follow-up time for OS was 14.42 months and 11.33 months in the satri-cel and TPC groups, respectively. TAKEAWAY In the intention-to-treat population, the median PFS was 3.25 months in the satri-cel group and 1.77 months in the TPC group. Satri-cel reduced the risk for progression or death by 63% (hazard ratio [HR], 0.37; P < .0001). Median OS showed improvement with satri-cel vs TPC (7.92 vs 5.49 months), although it did not reach statistical significance (HR, 0.69; P = .0416). < .0001). Median OS showed improvement with satri-cel vs TPC (7.92 vs 5.49 months), although it did not reach statistical significance (HR, 0.69; = .0416). The objective response rate was notably higher in the satri-cel group than in the TPC group (22% vs 4%), with disease control rates of 63% and 25%, respectively. The median duration of response was 5.52 months in the satri-cel group. Only two patients in the TPC group showed a partial response, with durations of 4.47 months and 5.42 months, respectively. The median duration of disease control was 3.61 months and 4.27 months in the satri-cel and TPC groups, respectively. All patients in the satri-cel group experienced treatment-emergent adverse events compared with 92% in the TPC group. Grade 3 or higher adverse events occurred in 99% of patients in the satri-cel group and 63% of those in the TPC group; the most common ones were decreased lymphocyte count (99%), decreased white blood cell count (98%), and cytokine release syndrome (95%). IN PRACTICE In this randomized, phase 2 study, "satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC, along with a manageable safety profile in patients with previously treated, advanced, CLDN18.2-positive gastric or gastroesophageal junction cancer," the authors write. SOURCE The study, led by Changsong Qi, MD, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumour, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute in Beijing, China, was published online May 31 in The Lancet . LIMITATIONS The sample size — powered for PFS — might be insufficient to yield definitive conclusions from the subgroup analyses. Some patients in the satri-cel group could not receive CAR T-cell infusion after apheresis, making them ineligible for treatment. The time between apheresis and CAR T-cell infusion remains a significant limiting factor, particularly in the case of those experiencing rapid disease progression. DISCLOSURES The study was funded by CARsgen Therapeutics, the National Key Research and Development Program of China, the National Natural Science Foundation of China, Beijing Hospitals Authority Youth Programme, Science Foundation of Peking University Cancer Hospital, Clinical Medicine Plus X—Young Scholars Project of Peking University, and the Peking University Clinical Scientist Training Program. Five authors declared being employees of CARsgen Therapeutics. The other authors declared no competing interests.
Yahoo
30-05-2025
- Business
- Yahoo
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study of patients with solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer - - Evopoint to receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved - TOKYO and SUZHOU, China, May 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2. The agreement grants Astellas a worldwide (excluding China's mainland, Hong Kong, Macao and Taiwan region) exclusive license to develop and commercialize XNW27011. XNW27011 is currently being evaluated in a Phase 1/2 study in China in patients with CLDN18.2-expressing solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer. It uses a proprietary topoisomerase I inhibitor payload and linker technology, an approach that has demonstrated clinical success in other approved cancer therapies. Astellas has significant expertise in developing therapies that target CLDN18.2, including VYLOYTM, the first CLDN18.2-targeted therapy approved in the world. XNW27011 has the potential to address currently unmet patient need and will expand Astellas' oncology pipeline which currently contains CLDN-targeting therapies utilizing different approaches, as well as ADC's directed to other targets. Under the terms of the agreement, Evopoint will receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved. Adam Pearson, Chief Strategy Officer, Astellas"Astellas is dedicated to advancing innovative therapies for some of the most challenging-to-treat cancers, such as gastric and pancreatic cancer. XNW27011 is a promising new asset that complements Astellas' pipeline and enhances our leading position in precision oncology. We look forward to harnessing our expertise in targeting CLDN18.2 and specialized knowledge in GI cancers to advance XNW27011 and deliver meaningful outcomes to patients." Arthur Qiang, Chairman, Evopoint"XNW27011 is a novel investigational antibody-drug conjugate that has shown great promise in the clinic. Astellas has a proven history of developing and commercializing a strong franchise of innovative cancer therapies. We are pleased to enter into this new license agreement to further our collective goals of bringing new treatment options for patients in need worldwide." About AstellasAstellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at About Evopoint BiosciencesEvopoint Biosciences is an innovative biopharmaceutical company with exceptional capabilities in R&D and commercialization. Since its inception, Evopoint has been committed to improving human health by discovering and developing cutting-edge pharmaceutical solutions that address significant unmet medical needs worldwide. Leveraging diverse discovery platforms in targeted therapy, ADC, and targeted protein degradation (TPD), the company has built a robust pipeline focused on oncology, infectious diseases and metabolic diseases. Learn more at Astellas Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. View original content to download multimedia: SOURCE Astellas Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
